Viridian Therapeutics Files 8-K on Financials
Ticker: VRDN · Form: 8-K · Filed: May 8, 2024 · CIK: 1590750
Sentiment: neutral
Topics: financial-reporting, corporate-actions
TL;DR
Viridian Therapeutics dropped an 8-K detailing their financials - check it for the latest on their operations.
AI Summary
Viridian Therapeutics, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The company, formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing provides an update on Viridian Therapeutics' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant risk disclosures.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- May 8, 2024 (date) — Date of earliest event reported
- Miragen Therapeutics, Inc. (company) — Former company name
- Signal Genetics, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Business address
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on May 8, 2024.
What were Viridian Therapeutics' previous company names?
Viridian Therapeutics was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
In which state is Viridian Therapeutics incorporated?
Viridian Therapeutics is incorporated in Delaware.
What is the business address of Viridian Therapeutics?
The business address is 221 Crescent Street, Bldg. 17, Suite 401, Waltham, MA 02453.
Filing Stats: 497 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-05-08 07:09:01
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value VRDN The Nasdaq Stock Mar
Filing Documents
- d823086d8k.htm (8-K) — 25KB
- d823086dex991.htm (EX-99.1) — 55KB
- g823086g0507115008419.jpg (GRAPHIC) — 3KB
- g823086g0508064241541.jpg (GRAPHIC) — 2KB
- 0001193125-24-133770.txt ( ) — 220KB
- vrdn-20240508.xsd (EX-101.SCH) — 3KB
- vrdn-20240508_lab.xml (EX-101.LAB) — 18KB
- vrdn-20240508_pre.xml (EX-101.PRE) — 11KB
- d823086d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits . Exhibit Number Exhibit Description 99.1 Press release, dated May 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Viridian Therapeutics, Inc. Date: May 8, 2024 By: /s/ Stephen Mahoney Stephen Mahoney President, Chief Executive Officer, and Director